prucalopride / Generic mfg. - LARVOL DELTA

OPTIMIZING CAPSULE ENDOSCOPY PATENCY TESTING: A NOVEL PROTOCOL USING GASTROGRAFIN, PRUCALOPRIDE, AND FASTING- A SINGLE CENTER EXPERIENCE (UEGW 2025) - No abstract available

Clinical

Prucalopride for Cognitive Functioning in Schizophrenia (clinicaltrials.gov) - P=N/A | N=34 | Not yet recruiting | Sponsor: University of Pittsburgh | Trial completion date: Aug 2026 ➔ Dec 2026 | Trial primary completion date: Mar 2026 ➔ Aug 2026

Trial completion date • Trial primary completion date • CNS Disorders • Psychiatry • Schizophrenia

Mechanistic Insights into Prucalopride's Role in IBS Treatment: Schwann-like Enteric Glial Cells as Therapeutic Targets. (PubMed, Gastroenterology) - No abstract available

Journal

Lupin receives US FDA approval for drug used to treat bowel disorder (CNBC-TV18) - "Drugmaker Lupin Ltd. informed the exchanges that it has received approval from the United States Food & Drug Regulator (USFDA) for a drug, which is used in the treatment of Chronic Idiopathic Constipation in adults (CIC). The USFDA has approved Lupin's Prucalopride Tablets, 1 mg, and 2 mg. These tablets are bioequivalent to Motegrity Tablets, 1 mg and 2 mg, of Takeda Pharmaceuticals U.S.A. Inc. According to the IQVIA data dated April 2025, the tablets had an estimated annual sales of $184 million in the US market."

ANDA • Sales • Constipation

PROVISIONAL EXPERT RECOMMENDATIONS FOR THE MANAGEMENT OF FECAL INCONTINENCE IN SYSTEMIC SCLEROSIS: A REPORT FROM WORLD SCLERODERMA FOUNDATION (WSF) GASTROINTESTINAL "AD HOC COMMITTEE" (EULAR 2025) - "(100%) Consider and prioritize pelvic physical therapy upfront for SSc-FI attributable to pelvic floor weakness before testing, as patients often improve and risk is minimal (if any) (100%) If overflow diarrhea is the issue and slow colonic transit is present, consider a trial of prokinetics (e.g., prucalopride or pyridostigmine). (83.3%) If slow colonic transit is not an issue, consider a trial of other medications (e.g., secretagogues, such as linaclotide, lubiprostone, plecanatide) to help alleviate stool burden... We present provisional recommendations for the evaluation and management of fecal incontinence in SSc. Only minimal refinement and voting is required to finalize these practical recommendations. Our collegiate approach will provide guidance for clinical practice and also inform a future research agenda."

Gastroenterology • Immunology • Rheumatology • Scleroderma • Systemic Sclerosis

Provisional expert recommendations for the management of refractory gastroesophageal reflux disease in systemic sclerosis: a report from the World Scleroderma Foundation (WSF) Gastrointestinal "Ad hoc committee" (EULAR 2025) - "In patients with refractory GERD and dysphagia, treatment with a promotility agent, such as prucalopride, pyridostigmine, domperidone, or metoclopramide, should be strongly considered as a therapeutic trial (100%)...In the context of refractory GERD and associated nausea, when promotility agents are suboptimal in managing symptoms, consider adding medications with anti-emetic properties (e.g., ondansetron, promethazine, mirtazapine) (85.7%)...Baclofen might be useful for patients with significant reflux episodes, with mainly weakly acidic or non-acidic on pH-impedance studies, and who show positive symptom association (78.6%)... We present provisional recommendations for the management of refractory GERD in SSc. Only minimal refinement and voting is required to finalize these practical recommendations. Our final recommendations shall also include ‘special circumstances’: ILD, myositis and CTD-overlap, and peri-lung transplant."

Gastroenterology • Gastroesophageal Reflux Disease • Gastrointestinal Disorder • Immunology • Infectious Disease • Myositis • Oncology • Osteoporosis • Pain • Rheumatology • Scleroderma • Systemic Sclerosis • Tobacco Cessation

Economic Burden of Patients With Chronic Idiopathic Constipation in the USA Before and After Prucalopride Initiation. (PubMed, Gastro Hep Adv) - "Some constipation-related HCRU and health care costs decreased after prucalopride initiation in patients with prior CIC medication use and males. In adults with CIC, constipation-related HCRU and medical costs decreased, while constipation-related health care costs and pharmacy costs increased 6 months after prucalopride initiation."

HEOR • Journal • Constipation • Gastroenterology • Gastrointestinal Disorder

Enhanced Intestinal Recovery with Prucalopride Succinate After Gastrectomy: Randomized Clinical Trial (IGCC 2025) - "Prucalopride enhances bowel motility and reduces inflammation after gastrectomy, supporting its inclusion in Enhanced Recovery protocols for gastric cancer patients."

Clinical • Gastric Adenocarcinoma • Gastric Cancer • Oncology • Solid Tumor

Bowel Blockage Without a Block: Amyloidosis Presenting as Chronic Intestinal Pseudo-Obstruction. (PubMed, Cureus) - "His symptoms showed partial improvement with prucalopride, but he continues to require total parenteral nutrition and a venting gastrostomy tube for symptom management. Amyloid subtyping and a bone marrow biopsy are pending to determine the underlying etiology."

Journal • Amyloidosis • Cardiomyopathy • Cardiovascular • CNS Disorders • Gastrointestinal Disorder • Immunology • Inflammatory Bowel Disease • Oncology • Pain • Psychiatry • Schizophrenia

EFFICACY OF PHARMACOLOGICAL TREATMENT IN PEDIATRIC INTESTINAL PSEUDO-OBSTRUCTION (DDW 2025) - "We identified the first instance each patient was treated with erythromycin, amoxicillin/clavulanic acid, prucalopride, pyridostigmine, or octreotide and recorded symptoms before and 1 month after starting the medication. Response to prokinetic medications was variable in our cohort of children with PIPO. While less than half improved with erythromycin, over half had some degree of improvement with prokinetics with a more generalized effect like prucalopride, pyridostigmine, and octreotide. Prospective studies are needed to further investigate this potential difference in prokinetic efficacy."

Clinical • Constipation • Gastroenterology • Gastrointestinal Disorder • Pain • Pediatrics

Pharmacokinetics and bioequivalence assessment of two prucalopride formulations in healthy Chinese women: a randomized, open-label, two-period, two-sequence, self-crossover study. (PubMed, Front Pharmacol) - "The generic and branded prucalopride tablets were bioequivalent in terms of PK parameters and demonstrated no clinically relevant differences in safety outcomes. http://www.chinadrugtrials.org.cn/clinicaltrials.prosearch.dhtml, identifier CTR20232669."

Journal • PK/PD data

Pharmacologic treatment of irritable bowel syndrome. Position statement of the Asociación Mexicana de Gastroenterología, 2024. (PubMed, Rev Gastroenterol Mex (Engl Ed)) - "Overall, these recommendations provide a solid framework for personalizing treatment, based on the clinical characteristics of the Mexican patient with IBS."

Clinical guideline • Journal • Constipation • Gastroenterology • Gastrointestinal Disorder • Pain

Ten-Year Trends in Pharmacologic Management of Gastroesophageal Reflux Disease and Pediatric Feeding Disorders in Young Children. (PubMed, J Pediatr) - "In this large, single-center study, prescriptions for young children with GERD or PFD declined over this 10-year period. There were substantial declines in PPI prescribing, contrasting with prior studies. These trends may indicate growing alignment of practice with consensus recommendations that advise against acid suppression as first-line management in this population."

Journal • Gastroenterology • Gastroesophageal Reflux Disease • Pediatrics

Pharmacologic Treatment of Irritable Bowel Syndrome with Predominant Constipation (PubMed, Korean J Gastroenterol) - "Guanylate cyclase-C agonists (linaclotide and plecanatide) enhance intestinal fluid secretion and motility, normalize bowel movements, and reduce abdominal pain. Na+/H+ exchanger inhibitors (e.g., tenapanor) decrease sodium absorption, increase fluid secretion, and alleviate visceral pain. Lubiprostone activates the chloride channels to facilitate bowel movements, while polyethylene glycol laxatives regulate osmotic pressure to improve stool consistency and ease defecation. Highly selective 5-HT4 agonists, such as prucalopride, accelerate gastrointestinal and colonic transit and improve stool frequency and consistency without increasing the cardiovascular risks raised in earlier agents such as tegaserod...These pharmacology agents have shown efficacy and safety in clinical studies, but drug availability, adverse effects, and variable patient responses are still challenging. Effective strategies to manage IBS-C require a personalized approach, considering the..."

Journal • Review • Cardiovascular • Constipation • Gastroenterology • Gastrointestinal Disorder • Immunology • Pain

Chronic, combinatorial targeting of NMDARs and 5-HT4Rs exerts extended behavioral effects against stress-induced perseverative behavior and hyponeophagia. (PubMed, Neuropsychopharmacology) - "Here, we evaluated whether administration of combinatorial (R,S)-ketamine, an NMDAR antagonist and Food and Drug Administration (FDA)-approved anesthetic, and prucalopride, a 5-HT type IV receptor (5-HT4R) agonist and FDA-approved drug for chronic idiopathic constipation (CIC), would have additional effects when administered after stress...Our results indicate that chronic administration of K + P has extended benefits for combating stress-induced pathophysiology. Our findings provide strong evidence that future clinical studies using this chronic treatment strategy may prove advantageous in decreasing a broad range of stress-induced psychiatric disorders."

Journal • Anesthesia • CNS Disorders • Constipation • Gastroenterology • Gastrointestinal Disorder • Mental Retardation • Psychiatry

Non-Invasive Auricular Acupoint Stimulation Improves Slow-Transit Constipation: Evidence From a Randomized Controlled Trial. (PubMed, Med Sci Monit) - "The study group, comprising 30 individuals, received a combination therapy of non-invasive auricular acupoint stimulation and prucalopride, while the control group, also consisting of 30 patients, was administered prucalopride as a monotherapy...Notably, the study cohort demonstrated a more pronounced decrease in neuropeptide Y and nitric oxide concentrations and a more substantial increase in colonic transit capacity and fecal water content compared to the control cohort (P<0.05). CONCLUSIONS Non-invasive auricular acupoint stimulation significantly enhances symptom relief in patients with slow-transit constipation, suggesting its potential as a complementary therapy for constipation management."

Clinical • Journal • Constipation • Gastroenterology • Gastrointestinal Disorder

Psychiatric Adverse Effects From Prucalopride in a Medically Complex Adolescent. (PubMed, Case Rep Pediatr) - "Clinicians should be aware of this possible side effect, particularly if considering administering prucalopride in patients with neurodevelopmental and psychiatric comorbid histories. Increased supervision and monitoring is recommended in these patients if prucalopride is administrated."

Adverse events • Journal • Constipation • Gastroenterology • Gastrointestinal Disorder • Immunology • Pain • Pediatrics • Psychiatry • Suicidal Ideation

Impact of Varying Doses of Prucalopride on Improving Gut Function Recovery After Elective Colorectal Surgery (clinicaltrials.gov) - P3 | N=180 | Recruiting | Sponsor: Future University in Egypt | Not yet recruiting ➔ Recruiting

Enrollment open

Evolution of the Chicago Classification: Bridging Physiology and Mechanics (clinicaltrials.gov) - P=N/A | N=575 | Recruiting | Sponsor: Northwestern University

New trial • Gastrointestinal Disorder • Rare Diseases

Prucalopride for Cognitive Functioning in Schizophrenia (clinicaltrials.gov) - P=N/A | N=34 | Not yet recruiting | Sponsor: University of Pittsburgh | Trial completion date: Feb 2026 ➔ Aug 2026 | Initiation date: Feb 2025 ➔ Jun 2025 | Trial primary completion date: Dec 2025 ➔ Mar 2026

Trial completion date • Trial initiation date • Trial primary completion date • CNS Disorders • Psychiatry • Schizophrenia

Magnetic particle imaging angiography of the femoral artery in a human cadaveric perfusion model. (PubMed, Commun Med (Lond)) - "This study demonstrates, that the recently developed human-sized MPI scanner facilitates reliable radiation-free image guidance for peripheral vascular interventions in the superficial femoral artery with a tracer approved for use in humans."

Journal

Novel gut-restricted bivalent agonists targeting mucosal 5-HT4R: Design, synthesis, and biological evaluation. (PubMed, Eur J Med Chem) - "Herein, we report for the first time the rational design and synthesis of gut-restricted bivalent agonists targeting mucosal 5-HT4R by integrating pharmacophores of prucalopride and tenapanor. Preclinical studies demonstrated that compound 4 significantly enhanced whole-gut and colonic transit, increased fecal output and water content, while maintaining minimal systemic absorption, confirming its gut-restricted nature. These findings underscore the feasibility of gut-restricted 5-HT4R agonists as a novel therapeutic strategy for CIC and provide valuable insights into the development of safer, more effective treatments for gastrointestinal disorders."

Journal • Constipation • Gastroenterology • Gastrointestinal Disorder

INTRATHECAL MORPHINE DELIVERED BY BACLOFEN PUMP FOR STATUS DYSTONICUS IN LESCH-NYHAN SYNDROME (SCCM 2025) - "Throughout the 42 hospitalization days (HD), he received intermittent benzodiazepines (HD 2-33), ketorolac (HD 1-23; 22 total doses), both intermittent (HD 3-24) and continuous infusions (HD 24-32) of ketamine, dantrolene (HD 3-41), prucalopride (HD 7-41), hydromorphone (HD 7-40), methadone (HD 15-20), cyclobenzaprine (HD 7-37), hyoscyamine (HD 13-39), amitriptyline (HD 19-41), and dexmedetomidine infusion (HD 20-35)...Gabapentin, previously avoided for history of allergic reaction, was started on HD 28...When the spine is inaccessible, utilization of preexisting intrathecal baclofen pump should be considered for delivery of opiates. More research is needed regarding long term safety, efficacy, and timing to optimize therapy and avoid polypharmacy."

Anesthesia • CNS Disorders • Dystonia • Immunology • Inflammatory Arthritis • Movement Disorders • Nephrology • Renal Calculi • Rheumatology

Application of in-silico docking for green electrochemical quantification of prucalopride succinate in pharmaceutical, urine, and milk matrices. (PubMed, Sci Rep) - "Concerning the statistical assessment, there weren't palpable disparities in functioning between the suggested technique and the published one. Concerning green assessment, the proposed technique surpassed the published techniques in both GAPI and analytical eco-scale metrics."

Journal

Expanding the Gastrointestinal Phenotype of 10p15.3 Microdeletion Syndrome: Refractory Atypical Gastroparesis in an Adult. (PubMed, Cureus) - "This case expands the GI phenotype associated with this rare syndrome and highlights the importance of recognizing motility disorders in patients with neurodevelopmental delays. Further studies are needed to explore the prevalence and underlying mechanisms of atypical gastroparesis in 10p15.3 microdeletion syndrome."

Journal • Developmental Disorders • Eosinophilic Esophagitis • Gastroenterology • Gastroesophageal Reflux Disease • Gastrointestinal Disorder • Genetic Disorders • Immunology • Pediatrics • SMYD3